Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Mechel increased sales of long products by 7% in 2022

3/23/23 MTLR

En+ Group reported for 2022 under IFRS

3/23/23 ENPG

Rosseti Kuban's IFRS profit in 2022 tripled

3/23/23 KUBE

Pyatyorochka started working in the Far East

3/23/23 FIVE

Rosseti Moscow Region reported for 2022 according to IFRS

3/23/23 MSRS

SPB Exchange creates DeFI and CFA development department

3/23/23 SPBE

Worthington Industries reports 9 months of fiscal year 2023

3/23/23 WOR

CSPC Pharmaceutical announces final Dividend for 2022

3/22/23 1093

Hengan International Group announces final dividends for 2022

3/22/23 1044

The Worthington Industries announced a quarterly dividend

3/22/23 WOR